Interest Expense of SUPERNUS PHARMACEUTICALS, INC. from 31 Mar 2011 to 31 Mar 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of the cost of borrowed funds accounted for as interest expense.
Summary: SUPERNUS PHARMACEUTICALS, INC. quarterly and annual Interest Expense in USD history and change rate from 31 Mar 2011 to 31 Mar 2024.
SUPERNUS PHARMACEUTICALS, INC. Interest Expense for the quarter ending 31 Mar 2024 was $0, a 100% decline year-over-year.
SUPERNUS PHARMACEUTICALS, INC. annual Interest Expense for 2021 was $19,696,000, a 1.3% increase from 2020.
SUPERNUS PHARMACEUTICALS, INC. annual Interest Expense for 2020 was $19,435,000, a 6.7% increase from 2019.
SUPERNUS PHARMACEUTICALS, INC. annual Interest Expense for 2019 was $18,207,000, a 32% increase from 2018.
Source SEC data: View on sec.gov

Interest Expense, Trailing 12 Months (USD)

Interest Expense, Quarterly (USD)

Interest Expense, YoY Quarterly Change (%)

Interest Expense, Annual (USD)

Interest Expense, YoY Annual Change (%)

SUPERNUS PHARMACEUTICALS, INC. Quarterly Interest Expense (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2024		$0	-$1,505,000	-100%	01 Jan 2024	31 Mar 2024	10-Q	08 May 2024	2024	Q1
Q3 2023		$0	-$1,724,000	-100%	01 Jul 2023	30 Sep 2023	10-Q	08 Nov 2023	2023	Q3
Q2 2023		$910,000	-$900,000	-50%	01 Apr 2023	30 Jun 2023	10-Q	08 Aug 2023	2023	Q2
Q1 2023		$1,505,000	-$437,000	-23%	01 Jan 2023	31 Mar 2023	10-Q	08 May 2024	2024	Q1
Q3 2022	$7,683,000	$1,724,000	-$4,201,000	-71%	01 Jul 2022	30 Sep 2022	10-Q	08 Nov 2023	2023	Q3
Q2 2022	$11,884,000	$1,810,000	-$3,657,000	-67%	01 Apr 2022	30 Jun 2022	10-Q	08 Aug 2023	2023	Q2
Q1 2022	$15,541,000	$1,942,000	-$4,155,000	-68%	01 Jan 2022	31 Mar 2022	10-Q	09 May 2023	2023	Q1
Q4 2021	$19,696,000	$2,207,000	+$430,000	+24%	01 Oct 2021	31 Dec 2021	10-K	13 Apr 2022	2021	FY
Q3 2021	$19,266,000	$5,925,000	-$163,000	-2.7%	01 Jul 2021	30 Sep 2021	10-Q	09 Nov 2022	2022	Q3
Q2 2021	$19,429,000	$5,467,000	-$348,000	-6%	01 Apr 2021	30 Jun 2021	10-Q	08 Aug 2022	2022	Q2
Q1 2021	$19,777,000	$6,097,000	+$342,000	+5.9%	01 Jan 2021	31 Mar 2021	10-Q	12 May 2022	2022	Q1
Q4 2020	$19,435,000	$1,777,000			01 Oct 2020	31 Dec 2020	10-K	13 Apr 2022	2021	FY
Q3 2020		$6,088,000	+$426,000	+7.5%	01 Jul 2020	30 Sep 2020	10-Q	05 Nov 2021	2021	Q3
Q2 2020		$5,815,000	+$426,000	+7.9%	01 Apr 2020	30 Jun 2020	10-Q	06 Aug 2021	2021	Q2
Q1 2020		$5,755,000			01 Jan 2020	31 Mar 2020	10-Q	07 May 2021	2021	Q1
Q3 2019		$5,662,000	+$1,288,000	+29%	01 Jul 2019	30 Sep 2019	10-Q	06 Nov 2020	2020	Q3
Q2 2019		$5,389,000	+$1,065,000	+25%	01 Apr 2019	30 Jun 2019	10-Q	17 Aug 2020	2020	Q2
Q4 2018	$13,840,000	$4,425,000			01 Oct 2018	31 Dec 2018	10-K	08 Mar 2021	2020	FY
Q3 2018		$4,374,000			01 Jul 2018	30 Sep 2018	10-Q	09 Nov 2018	2018	Q3
Q2 2018		$4,324,000	+$4,266,000	+7355%	01 Apr 2018	30 Jun 2018	10-Q	09 Aug 2018	2018	Q2
Q1 2018		$717,000	+$627,000	+697%	01 Jan 2018	31 Mar 2018	10-Q	10 May 2018	2018	Q1
Q2 2017	$316,000	$58,000	-$138,000	-70%	01 Apr 2017	30 Jun 2017	10-Q	09 Aug 2018	2018	Q2
Q1 2017	$454,000	$90,000	-$89,000	-50%	01 Jan 2017	31 Mar 2017	10-Q	10 May 2018	2018	Q1
Q4 2016	$543,000	$34,000	-$259,000	-115%	01 Oct 2016	31 Dec 2016	10-K	01 Mar 2019	2018	FY
Q3 2016	$802,000	$202,000	-$90,000	-31%	01 Jul 2016	30 Sep 2016	10-Q	09 Nov 2017	2017	Q3
Q2 2016	$892,000	$196,000	-$135,000	-41%	01 Apr 2016	30 Jun 2016	10-Q	03 Aug 2017	2017	Q2
Q1 2016	$1,027,000	$179,000	-$202,000	-53%	01 Jan 2016	31 Mar 2016	10-Q	09 May 2017	2017	Q1
Q4 2015	$1,229,000	$225,000	-$964,000	-81%	01 Oct 2015	31 Dec 2015	10-K	01 Mar 2018	2017	FY
Q3 2015	$2,193,000	$292,000	-$997,000	-77%	01 Jul 2015	30 Sep 2015	10-Q	20 Jan 2017	2016	Q3
Q2 2015	$3,190,000	$331,000	-$947,000	-74%	01 Apr 2015	30 Jun 2015	10-Q/A	23 Jan 2017	2016	Q2
Q1 2015	$4,137,000	$381,000	-$826,000	-68%	01 Jan 2015	31 Mar 2015	10-Q/A	20 Jan 2017	2016	Q1
Q4 2014	$4,963,000	$1,189,000	-$919,000	-44%	01 Oct 2014	31 Dec 2014	10-K	16 Mar 2017	2016	FY
Q3 2014	$5,882,000	$1,289,000	-$1,581,000	-55%	01 Jul 2014	30 Sep 2014	10-Q/A	20 Jan 2017	2015	Q3
Q2 2014	$7,463,000	$1,278,000	-$866,000	-40%	01 Apr 2014	30 Jun 2014	10-Q	07 Aug 2015	2015	Q2
Q1 2014	$8,329,000	$1,207,000	+$480,000	+66%	01 Jan 2014	31 Mar 2014	10-Q	06 May 2015	2015	Q1
Q4 2013	$7,849,000	$2,108,000	+$1,304,000	+162%	01 Oct 2013	31 Dec 2013	10-K/A	20 Jan 2017	2015	FY
Q3 2013	$6,545,000	$2,870,000	+$1,990,000	+226%	01 Jul 2013	30 Sep 2013	10-Q	12 Nov 2014	2014	Q3
Q2 2013	$4,555,000	$2,144,000	+$1,215,000	+131%	01 Apr 2013	30 Jun 2013	10-Q	12 Aug 2014	2014	Q2
Q1 2013	$3,340,000	$727,000	-$235,000	-24%	01 Jan 2013	31 Mar 2013	10-Q	13 May 2014	2014	Q1
Q4 2012	$3,575,000	$804,000	+$296,000	+58%	01 Oct 2012	31 Dec 2012	10-K	12 Mar 2015	2014	FY
Q3 2012	$3,279,000	$880,000	+$381,000	+76%	01 Jul 2012	30 Sep 2012	10-Q	13 Nov 2013	2013	Q3
Q2 2012	$2,898,000	$929,000	+$430,000	+86%	01 Apr 2012	30 Jun 2012	10-Q	14 Aug 2013	2013	Q2
Q1 2012	$2,468,000	$962,000	+$602,000	+167%	01 Jan 2012	31 Mar 2012	10-Q	15 May 2013	2013	Q1
Q4 2011	$1,866,000	$508,000			01 Oct 2011	31 Dec 2011	10-K	21 Mar 2014	2013	FY
Q3 2011		$499,000			01 Jul 2011	30 Sep 2011	10-Q	02 Nov 2012	2012	Q3
Q2 2011		$499,000			01 Apr 2011	30 Jun 2011	10-Q	13 Aug 2012	2012	Q2
Q1 2011		$360,000			01 Jan 2011	31 Mar 2011	10-Q	08 Jun 2012	2012	Q1

SUPERNUS PHARMACEUTICALS, INC. Annual Interest Expense (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2021	$19,696,000	+$261,000	+1.3%	01 Jan 2021	31 Dec 2021	10-K	13 Apr 2022	2021	FY
2020	$19,435,000	+$1,228,000	+6.7%	01 Jan 2020	31 Dec 2020	10-K	13 Apr 2022	2021	FY
2019	$18,207,000	+$4,367,000	+32%	01 Jan 2019	31 Dec 2019	10-K	13 Apr 2022	2021	FY
2018	$13,840,000	+$13,706,000	+10228%	01 Jan 2018	31 Dec 2018	10-K	08 Mar 2021	2020	FY
2017	$134,000	-$409,000	-75%	01 Jan 2017	31 Dec 2017	10-K	28 Feb 2020	2019	FY
2016	$543,000	-$686,000	-56%	01 Jan 2016	31 Dec 2016	10-K	01 Mar 2019	2018	FY
2015	$1,229,000	-$3,734,000	-75%	01 Jan 2015	31 Dec 2015	10-K	01 Mar 2018	2017	FY
2014	$4,963,000	-$2,886,000	-37%	01 Jan 2014	31 Dec 2014	10-K	16 Mar 2017	2016	FY
2013	$7,849,000	+$4,274,000	+120%	01 Jan 2013	31 Dec 2013	10-K/A	20 Jan 2017	2015	FY
2012	$3,575,000	+$1,709,000	+92%	01 Jan 2012	31 Dec 2012	10-K	12 Mar 2015	2014	FY
2011	$1,866,000			01 Jan 2011	31 Dec 2011	10-K	21 Mar 2014	2013	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.